INTRODUCTION

The term microbiota-gut-brain axis describes the complex bidirectional communication pathways linking the CNS with gut bacteria. This system has become a focus of neuroscience lately, as evidence provided by animal and human studies has documented the crucial role of the microbiota in regulating CNS homeostasis, cognitive development, and behavior. Over the last decade, by virtue of technological advances in the field of biomedicine, gut dysbiosis has been associated with the genesis or progression of a variety of neurological disorders,1 such as autism,2 multiple sclerosis,3 Parkinson’s disease,4,5 and Alzheimer’s disease.6 Recently, changes in the composition or function of gut microbiome have been linked to epilepsy and in particular to its medically refractory form7 Figure 1.

Epilepsy is a chronic neurological disorder “characterized by an enduring predisposition to generate seizures”8, with an estimated global prevalence of more than 50 million affected individuals and an annual incidence of 2.4 million patients.9 An estimated 35% of epilepsy cases are directly linked to a genetic background whereas in the remaining

Simela Chatzikonstantinou, Third Department of Neurology, Aristotle University of Thessaloniki, Thessaloniki, Greece

Georgia Gioula, Microbiology Department, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece

Vasilios K. Kimiskidis, Laboratory of Clinical Neurophysiology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece

Jack McKenna, Ioannis Mavroudis, Dimitrios Kazis, Leeds Teaching Hospitals, Leeds, UK

Correspondence
Simela Chatzikonstantinou, Third Department of Neurology, Aristotle University of Thessaloniki, 3 Arsaki street, Pefka, Thessaloniki, 57010, Greece. Email: melina.chatzik@gmail.com
cases, genetic risk in combination with acquired and environmental factors is considered to both contribute to epileptogenesis. Environmental causes may include cerebral insults such as trauma, tumors, strokes, traumatic brain injury, or infections. Classic epilepsy therapy involves antiepileptic medications, epilepsy surgery, vagus nerve stimulator (VNS), and ketogenic diet.

Despite recent advances in the discovery of new therapeutic drug agents for epilepsy, it is estimated that approximately one out of three patients with epilepsy is refractory to treatment. According to the definition by the International League Against Epilepsy (ILAE), drug-resistant epilepsy (DRE) implies that a patient has failed to achieve sustained seizure freedom after adequate trials of two tolerated, appropriately chosen and used antiepileptic drug schemes, whether as monotherapies or through a combination of drugs. Despite intensive research in the field, no advances in the effective therapeutic management of DRE have been made.

Currently, there is emerging evidence that alterations in gut microbiota composition and/or function exist in patients with DRE. Studies aiming to reveal gut dysbiosis in epilepsy are conducted in both pre- and clinical levels. Although research in the field had been halted for many years due to technological limitations, rapidly advancing sequence-based screening and the development of metagenomics and metabolomics that have flourished during the last decades have contributed greatly toward a better understanding of the role of gut dysbiosis in epilepsy.

The possibility for modifying gut microbiota using supplements like prebiotics, probiotics (collectively called symbiotics), or diets (eg, ketogenic diet) as add-on with antiepileptic drugs or alone has been keenly investigated during the last years. We hereby present a review of available literature concerning evidence for intestinal dysbiosis in DRE. It outlines the gut-brain axis connection; evidence of the link between microbiome, epileptogenesis, DRE, and treatment outcomes; and as proposed pathophysiological mechanisms and treatment studies. To our knowledge, there is only one published review with focus on intestinal dysbiosis and DRE. In this article, Holmes et al thoroughly review all existing literature regarding the gut microbiome's effect on treatments of patients with DRE (diets,}

**FIGURE 1** The gut microbiome effects on epilepsy are driven by environmental factors. On the right column (painted in red), we present the factors considered to provoke intestinal dysbiosis and indirectly induce epileptogenesis. On the left column, we present the factors that are assumed to enhance intestinal eubiosis. These are considered as potential therapeutic targets in drug-resistant epilepsy.

**Key Points**
- Approximately 1/3 of the world epilepsy population suffers from drug-resistant epilepsy
- Intestinal dysbiosis challenges brain homeostasis and seems to be present in patients with drug-resistant epilepsy
- The mechanism of action of the ketogenic diet might be mediated by alterations in the intestinal microbiota composition
- Overall, current evidence supports modification of gut microbiome, as a therapeutic target for drug-resistant epilepsy, but more research is necessary
pre-, probiotics, antibiotics, antiepileptic medications). In this review, we have added a section reporting findings of all clinical studies that have examined the intestinal microbiota composition in DRE cohorts.

2 | MICROBIOTA-GUT-BRAIN AXIS AND ITS ASSOCIATION WITH NEUROLOGICAL DISEASE

The term “gut-brain axis” refers to the bidirectional interactions between the gastrointestinal (GI) and the central nervous system (CNS). The CNS regulates the function and integrity of the GI tract through the neuroendocrine hypothalamic-pituitary-adrenal axis (HPA) and through the autonomic nervous system. These pathways regulate the permeability of the intestinal barrier, the motility of the GI tract, its secretory activity, and the composition of the intestinal microbiome. At the same time, the GI system can affect brain function and behavior by promoting synaptogenesis, activation of stress response, synthesis of neurotransmitters in the CNS, and blood-brain barrier (BBB) integrity. This symbiotic relationship between the brain and gut is mediated by the activity of enteric microbial populations, collectively known as “gut microbiota.” Recent discoveries have led to the emerging concept of the “microbiota-gut-brain (MGB) axis” which has attracted the interest of neuroscientists, during the last decades.21–23

The MGB axis collectively describes a network that includes gut microbiota and their metabolic products, enteric nervous system, autonomic nervous system (sympathetic and parasympathetic branches), neuroendocrine system, neural immune system, and central nervous system.19,24

Gastrointestinal microbiota colonize the GI tract and comprise trillions of microorganisms of about 1000 different species, including bacteria, fungi, yeasts, archaea, protozoa, and viruses. Bacteria are the most numerous species among commensal microbes (3.8 x 10^13 bacteria), and Firmicutes and Bacteroides are the most prevalent bacterial phyla among them.25 While the composition of the core gut microbiota is formed during the first year of life, dynamic changes may occur during the course of human development, driven by various stressors such as infection, drug, illness, and diet.19 Gut microbiome plays a crucial role in the development and maturation of the gut immune system, resistance to pathogens, carbohydrate metabolism, and metabolic homeostasis.26 It exerts its protective actions for the host through its byproducts (eg, short-chain fatty acids [SCFAs], cytokines, hormones, neurotransmitters) and neural activity (eg, ANS signaling modulation).25

The gut microbiome has been shown to affect CNS physiology and neurotransmission, through the neural network, neuroendocrine system, and metabolic and immune system.19,27 Gut microbial disbalance, namely dysbiosis, describes alterations in the taxonomic or functional profile of intestinal microbial communities relative to the community observed in healthy subjects.

3 | CAN THE MICROBIOME AFFECT SEIZURES? PRESUMPTIVE MECHANISMS THROUGH WHICH THE MICROBIOTA MODULATE SEIZURE SUSCEPTIBILITY

Animal and human studies have brought up evidence supporting dysbiosis as a causative factor of epilepsy, most often of a refractory form. There are five possible communication routes between gut microbiota and the brain. These include neural connections, the neuroendocrine HPA axis, biosynthesis of neurotransmitters by intestinal bacteria, the intestinal immune system, and lastly, interconnection between intestinal mucosal barrier and blood-brain barrier.19,24

At the same time, there are several pathophysiological pathways currently under research, possibly linking gut dysbiosis with epileptogenesis.28–32 The first mechanism involves the direct effect on neural networks through the release of neurotransmitters (specifically serotonin [5-HT], γ-aminobutyric acid [GABA] and glutamate), or their precursors (tryptophan and its metabolites) by gut bacteria.32,33 This affects the balance between excitation and inhibition within the CNS. The second mechanism involves neural signaling.29,31 Under homeostatic conditions, gut bacteria stimulate afferent neurons of the enteric nervous system (ENS) following stimulation via the vagus nerve that induces antiinflammatory activity. A disturbance in normal bacteria abundance or function might compromise this balance toward excess inflammation.34 Furthermore, the decrease in normal biosynthesis of short-chain fatty acids (butyric, propionic, acetic acids, etc) that possess a known antiinflammatory action, by the gut microbiota,35 is a potent pathogenetic mechanism of inducing secondary neuroinflammation that can trigger seizures. In addition, changes in the gut microbiome (composition or functional profile) may act by disrupting the HPA axis and normal response to stress,36 or by modulating the levels of brain-derived neurotrophic factor (BDNF) and therefore influence seizure mechanisms. Gut dysbiosis might also interfere with the endocannabinoid system,37,38 possibly linked to the pathogenesis of epilepsy. Finally, the occurrence of seizures, as well as epileptogenesis, might reflect a “leakage” in the integrity of the barrier system (intestinal mucosal barrier and blood-brain barrier) which is known to be affected by the gut microbiota. Changes in gut microbiome profile may lead to excess in lipopolysaccharide (LPS)-producing bacteria, that cause increased permeability of the intestinal immune barrier (by increased LPS levels).34,39 LPS
effect on seizure induction is mediated through upregulation of brain cytokines IL-1β, TNF, and COX-2. Consequently, peripheral produced inflammatory factors may act on the blood-brain barrier, increasing its permeability, and allowing pro-inflammatory mediators to enter the CNS Figure 2.

All in all, there seems to be various pathways of the MGB axis involved in the pathogenesis and maintenance of epileptic activity. Potential modifiers of these disturbances should aim to restore gut dysbiosis. Those include diet modifications, antibiotic, pre- or probiotic supplements and are currently intensively investigated, as they might represent potential therapeutic approaches for treating epilepsy, in the future.

4 | WHAT STUDIES SUGGEST A ROLE FOR MICROBIOTA IN DRE?

4.1 | Bacterial composition studies in DRE cohorts

It has been suggested that intestinal dysbiosis may contribute to the mechanism of DRE. A few recent, observational, or interventional clinical studies have searched for potential alterations in fecal microbiota profiles between DRE patients and healthy individuals, and/or drug-sensitive epileptic (DSE) patients. Their principal findings will be reviewed below.

Peng et al studied a cohort of 42 patients with DRE, 49 with DSE, and 65 matched healthy controls who were members of the patient families. Individuals from different groups were matched for age, sex, exposure to medication and included only subjects who had not received antibiotics or probiotics within the past 3 months and who had no other chronic disease except for epilepsy. Fecal samples were analyzed with the method of 16S rDNA sequencing, to map the participants’ gut microbiome composition. The results demonstrated important fecal microbiota alterations for the group of DRE patients as compared to both the two other groups, mainly concerning the increased abundance of rare flora, observed in the first group. (a) More precisely, the refractory epilepsy group microbiome synthesis presented increased α-diversity, which was more prevalent for the subgroup of those with four or more seizures per year than for those with less than four seizures per year. (b) When compared with the controls, the refractory group also revealed elevated levels of Firmicutes and decreased levels of Bacteroides. (c) More specifically, selected species from the phylum Firmicutes that were found to be increased included *Roseburia, Coprococcus, Ruminococcus*, and *Coprobacillus*. Comparison between DRE and DSE epilepsy groups showed relative abundance of *Methanobrevibacter, Fusobacterium, Neisseria*, and *Akkermansia* within the first group. Interestingly, the analysis of gut microbiome profile showed no important differences between DSE patients and healthy controls.

Another study with similar structure was recently published, by Gong et al. The researchers recruited a total of 55 patients with epilepsy (30 with DRE and 25 with DSE) and 46 controls, who were healthy spouses of the patients. Inclusion and exclusion criteria were similar to the above-mentioned study by Peng et al. Gut microbiome profiling was performed through 16S rDNA sequencing of stool samples. The authors reported substantial alterations of gut microbiota composition in the disease group including decreased α-diversity,
changes at the phylum level (increases in Actinobacteria and Verrucomicrobia and decreases in Proteobacteria) and at the genus level (increases in Prevotella_9, Blautia, Bifidobacterium). Of note, the results of subgroup analyses showed statistically important differences between the DRE, DSE, and control groups. Among patients with epilepsy, differences in the gut microbiota composition were reported depending on clinical phenotype (DRE or DSE), with DRE patients exhibiting enrichment of bacterial taxa in Actinobacteria, Verrucomicrobia, and Nitrospirae and the genera Blautia, Bifidobacterium, Subdoligranulum, Dialister, and Anaerostipes.43

Another cohort of pediatric population included 14 infants with medically refractory epilepsy and 30 age-matched healthy controls, whose microbiota profiling was done by 16S rDNA sequencing of stool samples. The calculation of α-diversity with the Shannon index for evenness revealed no statistically important difference between the two groups. After the principal component analysis, however, differences in fecal-microbial diversity among groups were assessed. More specifically, in the patient group they noted an increased relative abundance of Firmicutes and Proteobacteria in the microbiota from Actinobacteria, Verrucomicrobia, and Nitrospirae and the genera Blautia, Bifidobacterium, Subdoligranulum, Dialister, and Anaerostipes.43

Changes in microbiota composition:

| Reference            | Study design                  | Age group                                                                                      | Methodology                        | Reported changes in microbiota composition of drug-resistant patients |
|----------------------|-------------------------------|-------------------------------------------------------------------------------------------------|------------------------------------|-----------------------------------------------------------------------|
| Xie et al., 201744   | Retrospective cohort study    | Children. Patients (n = 14) and healthy infants (n = 30), mean age 1.95 (±3.10) years         | Fecal samples, 16s ribosomal DNA sequencing | ↓ α-diversity, ↑ Firmicutes and Proteobacteria (Cronobacter) ↓ Actinobacteria (Bifidobacterium) and Bacteroidetes (Bacteroides, Prevotella) |
| Peng et al., 201832  | Retrospective cohort study    | Adults. Drug-resistant patients (n = 42) and drug-sensitive patients (n = 49), and healthy controls from the same families (n = 65) | Fecal samples, 16s ribosomal DNA sequencing | ↑ α-diversity, more prevalent for the subgroup of those with four or more seizures per year than for those with less than four seizures per year. ↑ Firmicutes (Roseburia, Coprococcus, Ruminococcus, Coprobacillus) and ↓ Bacteroides. No important differences between DSE patients and healthy controls. |
| Lindefeldt et al., 201945 | Prospective observational study | Children and adolescents. Patients (n = 20) and healthy parents as controls (n = 11), age: 2-17 years | Fecal samples, Shotgun metagenomic sequencing | not significant differences in α-diversity, ↑ Firmicutes and Actinobacteria ↓ Proteobacteria and Bacteroidetes |
| Gong et al, 202043   | Retrospective cohort study    | Teenagers and adults, 15-60 years. 1. Exploration cohort: Drug-resistant patients (n = 40) and drug-sensitive patients (n = 20), and healthy controls, spouses (n = 46) 2. Validation cohort: patients (n = 13) and controls (n = 10) | Fecal samples, 16s ribosomal DNA sequencing | ↓ α-diversity, phylum level: ↑ Actinobacteria and Verrucomicrobia, ↓ Proteobacteria / genus level: ↑ Prevotella_9, Blautia, Bifidobacterium. Comparison between DRE and DSE: DRE patients ↑ taxa Actinobacteria, Verrucomicrobia, and Nitrospirae, ↑ genera Blautia, Bifidobacterium, Subdoligranulum, Dialister, and Anaerostipes. |

Abbreviation: DNA, deoxyribonucleic acid.
microbiome synthesis is largely known to display age dependency. There are limited publications covering this topic.

In the studies by Xie et al and Lindefeldt et al, an interventional branch with administration of ketogenic diet was performed, following the initial analysis. The corresponding findings are described below (ketogenic diet in DRE).

4.2 | Treatment studies in DRE

The notion that the gut microbiome influences seizure activity may be clarified through microbiota manipulation with probiotics, prebiotics, antibiotics, or diet, measuring clinical outcomes in prospective cohorts of patients with epilepsy. There are limited publications covering this topic.

4.3 | Ketogenic diet studies

4.3.1 | Ketogenic diet in DRE

The ketogenic diet (KD) is a nonpharmacologic therapeutic intervention, used in the management of medically refractory epilepsy since the 1920s, mostly in pediatric populations. It proposes high consumption of fat, in addition to sufficient protein and very restricted carbohydrate daily intake (the classic KD consists of a ratio between 2:1 and 4:1 of fat to protein and carbohydrates combined). Its hallmark feature is the production of ketone bodies (β-hydroxybutyrate, acetacetate, and acetone) in the liver from the dietary fat, a biochemical procedure called ketosis. Ketones substitute glucose as an energy substrate for ATP synthesis in body cells including brain cells. This systemic metabolic shift is considered to elucidate biochemical, metabolic, and hormonal changes that may ameliorate severity and reduce the frequency of epileptic seizures, although the exact mechanisms through which it exerts these actions remain unclear. KD is the therapy of choice for pyruvate dehydrogenase deficiency and for GLUT1 deficiency syndrome. Various clinical studies and meta-analyses have reported significantly positive results of the KD also in the management of DRE, mainly in children, but also in adults. Furthermore, it has been applied in various other types of childhood epilepsy and epileptic encephalopathies and has also been tried in other neurological disorders.

4.3.2 | Proposed mechanisms behind the therapeutic effects of the KD in DRE

Following the high effectiveness of the KD in the therapy of hard-to-treat epilepsies, there has been substantial scientific interest in defining the underlying pathways through which it exerts this action. It is highly probable that KD exerts its anticonvulsant effect through numerous mechanisms, which may vary with different types of epilepsy. The most widely described mechanisms include an increase in the expression of energy metabolism genes, a direct effect of polyunsaturated fatty acids on ion channels and neurotransmitters control. In addition to these, upregulation of neuroprotective factors such as calbindin, restriction of apoptotic factors like caspase 3, enhanced mitochondrial biogenesis, increased production of the inhibitory factor adenosine and reduction of pro-inflammatory cytokines have been described. Lately, it has been suggested that the intestinal microbiota may interfere with the KD mechanism of action. We will further discuss the role of gut microbiota on the antiepileptic action of KD. The current evidence suggests that the antiepileptic effect of the KD may be attributed to changes in the gut microbiota.

4.3.3 | Preclinical studies

Hampton proposes that intestinal microbes mediate the inhibitory impact on seizure activity, achieved by the KD. In a pivotal study of 2018, Olson et al studied two mouse models (one with 6-Hz induced seizures and the other with spontaneous tonic-clonic seizures) and showed that KD alters the gut microbiota and that this dietary modification was found to be protective against seizure activity in refractory epilepsy. More precisely, they noted that the KD reduced the microbial alpha diversity while simultaneously resulting in an increase in the abundance of Akkermansia muciniphila and Parabacteroides spp. Those mice that were treated with antibiotics were resistant to the anticonvulsant effect of KD. Only after colonization with both Akkermansia muciniphila and Parabacteroides spp did they regain the ability to benefit from the antiepileptic effect of KD. The authors described how microbiota transformation led to alterations in the colonic luminal, serum, and hippocampal metabolome, mainly associated with amino acid metabolism. The decline in peripheral subsets of ketogenic gamma-glutamylated amino acids that serve as substrates for the synthesis of γ-aminobutyric acid (GABA) led to the consequent increase in hippocampal GABA inhibitory neurotransmitter, relative to glutamate excitatory neurotransmitter levels, in KD-fed mice compared with controls. These modifications in neurotransmitters’ expression were correlated with the antiseizure effect of the KD. More extensive research is required to ascertain whether similar biological pathways’ modifications (alterations in amino acids and neurotransmitters’ expression) take place in humans on a ketogenic diet.
4.3.4 | Clinical studies

A few studies in humans have also reported evidence about alterations of gut microbiota in patients with epilepsy after KD, although their results are not unanimous.44–45,62–64 A case-control study by Xie et al44 which included 14 DRE children who received KD and 30 healthy controls showed vast differences of the gut microbiome compositions between the two groups. Also, in the group of the patients, serial examinations of intestinal microflora revealed changes in microbiota populations along the course of the treatment. The authors identified a reduction in pathogenic Proteobacteria (specifically Cronobacter) and an increase in the beneficial Bacteroidetes (specifically Bifidobacterium, Bacteroides, and Prevotella) within one week of commencing the ketogenic diet. These changes to the intestinal microflora were considered to correlate with suppression of seizure activity.44 Zhang et al prospectively analyzed gut microbiota changes in 20 children with DRE after a 6-month treatment with KD. The authors reported different patterns of modification of intestinal microflora as well as different levels of response in terms of antiseizure result, in the above group of patients. In general, the microflora profiles of the studied population showed reduced levels of Firmicutes and Actinobacteria and increased levels of Bacteroidetes, after the treatment. A subgroup analysis revealed that those with no response to treatment (<50% reduction of seizures) had a corresponding increase in the levels of Alistipes, Clostridia, Lachnospiraceae, Ruminococcaceae, and Rikenellaceae compared to the responders. This study raised an important issue about the varying efficacy of the KD in drug-resistant epilepsy that requires investigation by future studies.62

Another case-control study included 12 children with DRE and analyzed the fecal-microbial composition of the cohort before and after a 3-month treatment with the KD. After the treatment, there was a reduction in the relative abundance of Dialister, Actinobacteria, Bifidobacteria, and Eubacterium rectale with a simultaneous increase in the relative abundance of Escherichia coli. Lindfeldt et al45 mentioned that the above findings raise important concerns about the general health of patients receiving KD, since they are indicative of a decrease in relative abundance of health-promoting, fiber-consuming bacteria, in response to the diet.

In a similar three-month prospective study of Tagliabue et al, DRE children with GLUT1 deficiency syndrome demonstrated a marked increase in levels of Desulfovibrio spp., but showed no changes in Bacteroides and Firmicutes following the KD.63 Last, Ramm-Pettersen et al64 found elevated levels of Desulfovibrio spp. in the intestines of six GLUT1 deficiency patients after 3 months of KD. This species has been linked to increased intestinal inflammation following ingestion of animal fat.63,65

4.4 | Fecal transplant studies

In the literature, there is only one case report correlating gut microbiome modulation to difficult-to-treat epilepsy. The authors reported on a patient with a long history of epilepsy and concomitant Crohn’s disease, who became seizure-free after fecal microbiota transplantation (FMT), and surprisingly retained remission even after the cessation of the antiepileptic regimen. This article brought up an innovative potential mechanism involved in epileptogenesis and stressed the need for intensive research efforts to unravel the link between gut microbiome and epilepsy.66

4.5 | Antibiotic studies

Indirect evidence for the potential benefit of regulating gut microbiota in seizure suppression though antibiotic treatment can be derived from the following retrospective study, by Braakman and Van Ingen. In this study, researchers reported that five out of six patients with DRE became seizure-free during antibiotic treatment, the sixth had a significant reduction in seizure frequency and the improvement was sustained for two weeks after the antibiotic treatment cessation. The authors speculated that this beneficial effect of antibiotics on seizure frequency might be mediated by alterations in the gut microbiome, although this could not be objectively proven, since no microbiota profiling was performed.67

4.6 | Probiotic studies

There is only one published clinical trial reporting on the administration of probiotics to patients with refractory epilepsy. Gómez-Eguilaz et al reported on the effects of four-month probiotic supplementation, with a combination of Lactobacillus, Bacteroides and Streptococcus subspecies, in 45 patients with drug-resistant epilepsy. Following intervention, patients displayed a reduction in seizure frequency (≥50% in 28.9% of the patients) and improvement in quality of life, assessed by Quality of Life score (mean ± SD: 19.23 ± 6.04 vs 26.45 ± 9.7; P = .013). Overall, this study reveals that probiotics might constitute a safe, low-cost and effective supplementary therapy in patients with DRE. However, whether therapeutic effects of probiotics are mediated by modifications in gut microbiome could not be established, since, again, microbiota analysis was not performed.68 No studies about prebiotic supplementation in drug-resistant epilepsy have been published yet.
5 | FUTURE DIRECTIONS

The study of the enteric microbiome in DRE represents a promising area for the enhancement of epilepsy care. Gut microbiome “profiling” could potentially serve as a biomarker in epilepsy management. Once the alterations in the composition or function of gut microbiota in refractory epilepsy are clarified, this could be used in clinical practice in order to identify drug resistance from an early stage and treat patients with more targeted interventions (eg, KD, probiotics, and prebiotics). This would require the conduction of large studies, recruiting cohorts of patients who have experienced the first seizure (or early in the course of the disease) and prospective analysis and examination of their gut microbiome, in association with the progress of the disease (number of seizures, response to treatment, etc). Furthermore, gut microbiome analysis might be used to monitor response to treatment in those patients treated with microbiota-targeted therapies. The impact of antiepileptic drug treatment on gut microbiota, and vice versa, should be investigated by future studies. Like many other, nonantibiotic drugs, it is assumed that some of the antiepileptic drugs might influence gut bacteria growth and survival. Such evidence is derived from animal studies involving AEDs and their effects on gut microbiota, however, no studies in humans have been conducted so far. On the other hand, the gut microbiome can affect drug metabolism altering absorption, bioavailability and efficacy of the medication, through various direct and indirect mechanisms. Furthermore, future research may establish whether altering bacterial composition may serve in the management of refractory epilepsy through antibiotics, pre- or probiotic supplementation and FMT. The overall side effects of the KD for the general health of the patients in terms of microbiota modifications will also need to be established. Finally, there is a need to expand the research of gut dysbiosis as a contributor to epileptogenesis, beyond the DRE patients. Alterations of the gut microbiome might also be present in non–drug-resistant epileptic cases, and this remains to be studied.

6 | CONCLUSION

There is some evidence for a difference in the enteric microbial composition between those with refractory epilepsy and both healthy control and nonrefractory epileptic groups. We note a consensus among studies concerning increased prevalence of Firmicutes relative to Bacteroides in individuals with refractory epilepsy. However, detailed taxonomic analysis revealed considerable variations in the proportions of reported taxa among the studies. Furthermore, the conclusions were conflicting as to whether α-diversity is altered in the drug-resistant epilepsy microbiota populations.

Comparison of the structure and composition of the fecal microbiota among epileptic patients with different clinical phenotypes (DRE and DSE) has so far been conducted by two studies. In the study by Peng et al, the DSE group showed no statistically important differences compared to controls, while, in the study by Gong et al, it was reported that both DRE and DSE patients exhibited alterations in gut microbiota composition compared to controls. After further analysis, DRE patients’ intestines were found to be more dysbiotic, compared to DSE, with an increased abundance in rare flora. It is possible that, once the alterations of fecal microbiota properties among different epileptic groups are adequately studied, gut profiling could serve as a potential biomarker for disease prognosis, in clinical practice.

Importantly, there are certain inherent limitations to the study design and instruments that were used. Firstly, many of the studies included relatively small sample sizes. Also, there is a lack of homogeneity among the studies with regard to the age of subjects and the sequencing methodology used to create gut microbiota profiles. The evidence should be judged with caution since the impact of genetic and environmental factors on the composition of the gut microbiota was not evaluated in any of the studies. This may be an important confounding factor of the reported results.

There has been limited research conducted so far, concerning the interventions aiming to alter the enteric microbiota as a potential treatment in DRE. Proposed modifications include probiotics, prebiotics, antibiotics, or dietary modifications. The KD diet is already used for medically refractory epilepsy although the exact mechanism for its therapeutic effects is still not completely understood.

In spite of the limitations, research and clinical study findings suggest that gut microbiome sequencing merits further investigation as a potential biomarker in DRE. There is a need for replicating these findings in large cohorts with adequate control populations, considering variables like age, environmental exposure including medication and diet, genetic factors, and comorbidities. The use of unified microbiome analysis protocols, including both taxa and metabolomic analysis, would provide more extensive and comparable results, between studies. Preliminary study evidence shows promising results; however, more research is warranted so that these modifications might be considered as “evidence-based.”

ACKNOWLEDGMENTS
None.

CONFLICT OF INTERESTS
None of the authors has any conflict of interest to disclose. We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.
REFERENCES

1. Gogou M. The involvement of the intestinal microbiome in neuropsychiatric diseases. Arch Helv Med. 2017;34(5):628–35.
2. Muller JG, Sharp WG, Cubells JF. The gut microbiome: a new frontier in autism research. Curr Psychiatry Rep. 2013;15(2):337.
3. Jangi S, Gandhi R, Cox LM, Li N, von Glehn F, Yan R, et al. Alterations of the human gut microbiome in multiple sclerosis. Nat Commun. 2016;28(7):12015.
4. Parashar A, Udayabanu M. Gut microbiota: Implications in Parkinson's disease. Parkinonism Relat Disord. 2017;7(38):1–7.
5. Ilie OD, Ciobica A, McKenna J, Dorofei B, Mavroudis I. Mini-review on the relations between gut microflora and Parkinson’s disease: further biochemical (oxidative stress), inflammatory, and neurological particularities. Oxid Med Cell Longev. 2020;2020:4518023.
6. Jiang C, Li G, Huang P, Liu Z, Zhao B. The gut microbiota and Alzheimer's disease. J Alzheimers Dis. 2017;58(1):1–15.
7. Lum GR, Olson CA, Hsiao EY. Emerging roles for the intestinal microbiome in epilepsy. Neurobiol Dis. 2020;135:104576.
8. World Health Organization. Epilepsy. June 20 2019. https://www.who.int/news-room/fact-sheets/detail/epilepsy. Accessed April 20, 2020.
9. Shorvon SD, Andermann F, Guerrini R. The causes of epilepsy. Cambridge, UK: Cambridge University Press; 2011.
10. Pérez-Pérez D, Friais-Soria CL, Rocha L. Drug-resistant epilepsy: From multiple hypotheses to an integral explanation using preclinical resources. Epilepsy Behav. 2019;1:106430.
11. Kwan P. Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Low. Drug-resistant epilepsy: past 25 years and beyond. Seizure. 2017;44:147–56.
12. Golyaha A, Kwan P. Drug development for refractory epilepsy: the next 25 years and beyond. Seizure. 2017;44:147–56.
13. Dahlin M, Prast-Nielsen S. The gut microbiome and epilepsy. EBioMedicine. 2019;44:741–6.
14. Song Ej, Lee ES, Do NY. Progress of analytical tools and techniques for human gut microbiome research. J Microbiol. 2018;56(10):693–705.
15. Knight R, Vrbanac A, Taylor BC, Aksenov A, Callewaert C, et al. Best practices for analysing microbiomes. Nat Rev Microbiol. 2018;16(7):410–22.
16. Mooser C, Gomez de Agüero M, Ganal-Vonarburg SC. Standardization in host–microbiota interaction studies: challenges, gnotobiology as a tool, and perspective. Curr Opin Microbiol. 2018;44:50–60.
17. De Caro C, Iannone LF, Citarro R, Striano P, De Sarro G, Constanti A, et al. Can we 'seize' the gut microbiota to treat epilepsy? Neurosci Biobehav Rev. 2019;107:750–64.
18. Holmes M, Flaminio Z, Vardhan M, Xu F, Li X, Devinsky O, et al. Cross talk between drug-resistant epilepsy and the gut microbiome. Epilepsia. 2020;61(12):2619–28.
19. Wang HX, Wang YP. Gut Microbiota-brain Axis. Chin Med J (Engl). 2016;129(19):2373–80.
20. Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci. 2012;13(10):701–12.
21. Mayer EA, Knight R, Mazmanian SK, Cryan JF, Tillisch K. Gut microbes and the brain: Paradigm shift in neuroscience. J Neurosci. 2014;34:15490–6.
22. Smith PA. The tantalizing links between gut microbes and the brain. Nature. 2015;526:312–4.
23. Schmidt C. Mental health: Thinking from the gut. Nature. 2015;518:S12–S15.
24. Mayer EA, Tillisch K, Gupta A. Gut-brain axis and the microbiota. J Clin Invest. 2015;125(3):926–38.
25. Kho Z, Lal SK. The human gut microbiome - a potential controller of wellness and disease. Front Microbiol. 2018;14(9):1835.
26. Tremaroli V, Bäckhed F. Functional interactions between the gut microbiota and host metabolism. Nature. 2012;489(7415):242–9.
27. Heijtz RD, Wang S, Anuar F, Qian Y, Bjorkholm B, Samuelsson A, et al. Normal gut microbiota modulates brain development and behavior. Proc Natl Acad Sci USA. 2011;108:3047–52.
28. Erny D, Hrabé de Angelis AL, Jaitin D, Wieghofer P, Staszewski O, David E, et al. Host microbiota constantly control maturation and function of microglia in the CNS. Nat Neurosci. 2015;18:965–77.
29. Warner BB. The contribution of the gut microbiome to neurodevelopment and neuropsychiatric disorders. Pediatr Res. 2019;85(2):216–24.
30. Foster JA, Rinaman L, Cryan JF. Stress & the gut-brain axis: Regulation by the microbiome. Neurobiol Stress. 2017;19(7):124–36.
31. Dinan TG, Cryan JF. Gut-brain axis in 2016: Brain-gut-microbiota axis-mood, metabolism and behaviour. Nat Rev Gastroenterol Hepatol. 2017;14(2):69–70.
32. Bravo JA, Forsythe P, Chew MV, Escaravage E, Savignac HM, Dinan TG, et al. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci U S A. 2011;108(38):16050–5.
33. O’Mahony SM, Clarke G, Borre YE, Dinan TG, Cryan JF. Serotonin, tryptophan metabolism and the brain-gut-microbiota axis. Behav Brain Res. 2015;257(277):32–48.
34. Blander JM, Longman RS, Iliev ID, Sonnenberg G, Artis D. Regulation of inflammation by microbiota interactions with the host. Nat Immunol. 2017;18:851–60.
35. van de Wouw M, Boehme M, Lyte JM, Strain C, O’Sullivan O, et al. Short-chain fatty acids: microbial metabolites that alleviate stress-induced brain–gut axis alterations. J Physiol. 2018;596:4923–44.
36. Sudo N, Chida Y, Aiba Y, Sonoda J, Oyama N, Yu X-N, et al. Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice. J Physiol. 2004;558:263–75.
37. Al-Ghezi ZZ, Busbee PB, Alghetaa H, Nagarkatti PS, Nagarkatti M. Combination of cannabinoids, delta-9- tetrahydrocannabinol (THC) and cannabidiol (CBD), mitigates experimental autoimmune encephalomyelitis (EAE) by altering the gut microbiome. Brain Behav Immun. 2019;82:25–35.
38. Mehrpoura-Bahrami P, Chitraula KN, Ganewatta MS, Tang C, Murphy EA, Enos RT, et al. Blockade of CB1 cannabinoid receptor alters gut microbiota and attenuates inflammation and diet-induced obesity. Sci Rep. 2017;7:15645.
39. Balosso S, Liu J, Bianchi ME, Vezzani A. Disulfide-containing peptides of the gut microbiota: Implications in Alzheimer’s disease and the brain. Oxid Med Cell Longev. 2020;2020:4518023.
40. Lum GR, Olson CA, Hsiao EY. Emerging roles for the intestinal microbiome in epilepsy. Neurobiol Dis. 2020;135:104576.
40. Maroso M, Balosso S, Ravizza T, Liu J, Aronica E, Iyer AM, et al. Toll-like receptor 4 and high-mobility group box-1 are involved in icotogenesis and can be targeted to reduce seizures. Nat Med. 2010;16:413–9.
41. Wu J, Zhang Y, Yang H, Rao Y, Miao J, Lu X. Intestinal microbiota as an alternative therapeutic target for epilepsy. Can J Infect Dis Med Microbiol. 2016;2016:9032809.
42. Peng A, Qiu X, Lai W, Li W, Zhang L, Zhu XI, et al. Altered composition of the gut microbiome in patients with drug-resistant epilepsy. Epilepsy Res. 2018;147:102–7.
43. Gong X, Liu XU, Chen C, Lin J, Li A, Guo K, et al. Alteration of gut microbiota in patients with epilepsy and the potential index as a biomarker. Front Microbiol. 2020;18(11):517797.
44. Xie G, Zhou Q, Qiu C-Z, Dai W-K, Wang H-P, Li Y-H, et al. Ketogenic diet poses a significant effect on imbalanced gut microbiota in infants with refractory epilepsy. World J Gastroenterol. 2017;23:6164–71.
45. Lindefeldt M, Eng A, Darban H, Bjerkner A, Zetterström CK, Allander T, et al. The ketogenic diet influences taxonomic and functional composition of the gut microbiota in children with severe epilepsy. NPJ Biofilms Microbiomes. 2019;23(5):5.
46. Peterman MG. The ketogenic diet in the treatment of epilepsy: A preliminary report. Am J Dis Child. 1924;28(1):28–33.
47. Rogawski MA, Löscher W, Rho JM. Mechanisms of action of antiseizure drugs and the ketogenic diet. Cold Spring Harb Perspect Med. 2016;6(5):a022780.
48. D'Andrea Meira I, Romão TT, Pires do Prado HJ, Krüger LT, Pires MEP, da Conceição PO. Ketogenic diet and epilepsy: what we know so far. Front. Neurosci. 2019;13:5.
49. Ulamek-Kozioł M, Czuczwar SJ, Januszewski S, Pluta R. Ketogenic diet and epilepsy. Nutrients. 2019;11(10):2510.
50. Tang M, Park SH, De Vivo DC, Monani UR. Therapeutic strategies for glucose transporter 1 deficiency syndrome. Ann Clin Transl Neurol. 2019;6(9):1923–32.
51. Neal EG, Chaffe H, Schwartz RH, Lawson MS, Edwards N, Fitzsimmons G, et al. The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial. Lancet Neurol. 2008;7(6):500–6.
52. Lambrechts DAJE, de Kinderen RJA, Vles JSH, de Louw AJA, Aldenkamp AP, Majoie HJM. A randomized controlled trial of the ketogenic diet in refractory childhood epilepsy. Acta Neurol Scand. 2017;135(2):231–9.
53. Martin-McGill KJ, Jackson CF, Bresnahan R, Levy RG, Cooper PN. Ketogenic diets for drug-resistant epilepsy. Cochrane Database Syst Rev. 2018;11:CD001903.
54. Liu H, Yang YI, Wang Y, Tang H, Zhang F, Zhang Y, et al. Ketogenic diet for treatment of intractable epilepsy in adults: a meta-analysis of observational studies. Epilepsia Open. 2018;3:9–17.
55. Kelley SA, Koss EH. Doose syndrome (myoclonic-astatic epilepsy): 40 years of progress. Dev Med Child Neurol. 2010;52:988–93.
56. Laux L, Blackford R. The ketogenic diet in Dravet syndrome. J Child Neurol. 2013;28:1041–4.
57. Pires ME, Ilea A, Bourel E, Bellavoine V, Merdariu D, Berquin P, et al. Ketogenic diet for infantile spasms refractory to first line treatments: An open prospective study. Epilepsy Res. 2013;105:189–94.
58. Kraeuter AK, Guest PC, Sarnyai Z. The Therapeutic Potential of Ketogenic Diet Throughout Life: Focus on Metabolic, Neurodevelopmental and Neurodegenerative Disorders. Adv Exp Med Biol. 2019;1178:77–101.
59. Dupuis N, Curatolo N, Benoist JF, Auvin S. Ketogenic diet exhibits anti-inflammatory properties. Epilepsia. 2015;56:e95–8.
60. Hampton T. Gut microbes may account for the anti-seize effects of the ketogenic diet. JAMA. 2018;320(13):1307.
61. Olson CA, Vuong HE, Yano JM, Liang QY, Nusbaum DJ, Hsiao EY. The gut microbiota mediates the anti-seize effects of the ketogenic diet. Cell. 2018;173(1728–41):e13.
62. Zhang Y, Zhou S, Zhou Y, Yu L, Zhang L, Wang Y. Altered gut microbiome composition in children with refractory epilepsy after ketogenic diet. Epilepsy Res. 2018;145:163–8.
63. Tagliafuoco A, Ferraris C, Uggeri F, Trentani C, Bertoli S, de Giorgis V, et al. Short-term impact of a classical ketogenic diet on gut microbiota in GLUT1 deficiency syndrome: A 3-month prospective observational study. Clin Nutr Espen. 2017;17:33–7.
64. Ramm-Pettersen A, Nakken KO, Haavardsholm KC, Selmer KK. GLUT1-deficiency syndrome: Report of a four generation Norwegian family with a mild phenotype. Epilepsy Behav. 2017;70(PT A):1–4.
65. Fan Y, Wang H, Liu X, Zhang J, Liu G. Crosstalk between the ketogenic diet and epilepsy: from the perspective of gut microbiota. Mediators Inflamm. 2019;3(2019):8373060.
66. He Z, Cui B-T, Zhang T, Li P, Long C-Y, Ji G-Z, et al. Fecal microbiota transplantation cured epilepsy in a case with Crohn’s disease: the first report. World J Gastroenterol. 2017;23(19):3565–8.
67. Braakman HM, van Ingen J. Can epilepsy be treated by antibiotics? J Neurol. 2018;265:1934–6.
68. Gómez-Eguílaz M, Ramón-Traper JL, Pérez-Martínez L, Blanco JR. The beneficial effect of probiotics as a supplementary treatment in drug-resistant epilepsy: a pilot study. Benef Microbes. 2018;9(6):875–81.
69. Esiobu N, Hoosein N. An assessment of the in vitro antimicrobial effects of two antiepileptic drugs - Sodium valproate and phenytoin. Antonie van Leeuwenhoek, Int J Gen Mol Microbiol. 2003;83:63–8.
70. Kitaamura S, Sugihara K, Kuwasako M, Tatsumi K. The role of mammalian intestinal bacteria in the reductive metabolism of zonisamide. J Pharm Pharmacol. 1997;49:253–6.
71. Zimmermann M, Zimmermann-Kogadeeva M, Wegmann R, Goodman AL. Separating host and microbiome contributions to drug pharmacokinetics and toxicity. Science. 2019;8:363.
72. Clarke G, Sandhu KV, Griffin BT, Dinan TG, Cryan JF, Hyland NP. Gut reactions: breaking down xenobiotic–microbiome interactions. France CP, editor. Pharmacol Rev. 2019;71:198–224.

How to cite this article: Chatzikonstantinou S, Gioula G, Kimiskidis VK, McKenna J, Mavroudis I, Kazis D. The gut microbiome in drug-resistant epilepsy. Epilepsia Open. 2021;6:28–37. https://doi.org/10.1002/epi4.12461